Dr. Adeel Khan

Just like, you know, I was an early adopter of Tesla personally. I bought an electric vehicle before anyone else really did. And I was, I was, and, but now it's becoming much more common. And so I think it's going to be the same thing with this, where it's like, okay, there's going to be the early adopters. There's going to be people who are more into this stuff.

Just like, you know, I was an early adopter of Tesla personally. I bought an electric vehicle before anyone else really did. And I was, I was, and, but now it's becoming much more common. And so I think it's going to be the same thing with this, where it's like, okay, there's going to be the early adopters. There's going to be people who are more into this stuff.

And, and it also, I think the way to think about it is if you have the means to do this stuff, you're kind of, you are paving a better way for a future of people because we're at least our company.

And, and it also, I think the way to think about it is if you have the means to do this stuff, you're kind of, you are paving a better way for a future of people because we're at least our company.

You know, we're investing all of our profits back into R&D and trying to push this field forward and trying to really make a difference in regenerative medicine, you know, as opposed to just trying, you know, as opposed to just kind of using it just for profit for yourself type of thing.

You know, we're investing all of our profits back into R&D and trying to push this field forward and trying to really make a difference in regenerative medicine, you know, as opposed to just trying, you know, as opposed to just kind of using it just for profit for yourself type of thing.

So, and that's why I'm, but the only way to push this bill forward is you have to, at the end of the day, do controlled clinical trials because that's the only way you're going to get insurance companies and regulators to buy into this. And that's the long game.

So, and that's why I'm, but the only way to push this bill forward is you have to, at the end of the day, do controlled clinical trials because that's the only way you're going to get insurance companies and regulators to buy into this. And that's the long game.

But by being able to offer these offshore treatments that people are willing to pay for and people actually get real results for, they're funding our ability to do the research, which ultimately will be used as justification for regulators to approve it, which I think will take probably seven to 10 years, you know, in terms of getting approvals for specific medical conditions.

But by being able to offer these offshore treatments that people are willing to pay for and people actually get real results for, they're funding our ability to do the research, which ultimately will be used as justification for regulators to approve it, which I think will take probably seven to 10 years, you know, in terms of getting approvals for specific medical conditions.

Like I think osteoarthritis, for example, is not very far away. We're already getting incredible results with the new cells and hydrogel scaffold, which is kind of, you know, like a jello that protects the stem cells and allows them to stay there so they don't migrate. And the results are already incredible.

Like I think osteoarthritis, for example, is not very far away. We're already getting incredible results with the new cells and hydrogel scaffold, which is kind of, you know, like a jello that protects the stem cells and allows them to stay there so they don't migrate. And the results are already incredible.

And, you know, but just before I came on this call with you, I was talking, we're working with a company that's making custom scaffolds using 3D bioprinting. And that can actually resurface an entire joint. And they've already done that in large animal studies. So the human trials are next. And that's what we're going to do. And so this stuff is not that far away.

And, you know, but just before I came on this call with you, I was talking, we're working with a company that's making custom scaffolds using 3D bioprinting. And that can actually resurface an entire joint. And they've already done that in large animal studies. So the human trials are next. And that's what we're going to do. And so this stuff is not that far away.

Yeah, I mean, look, in Japan, I keep bringing up Japan because they're just so far ahead of us. But in Japan, they actually cover intraarticular stem cell injections. for knee osteoarthritis and cartilage defects. And so, and those are culture expanded stem cells.

Yeah, I mean, look, in Japan, I keep bringing up Japan because they're just so far ahead of us. But in Japan, they actually cover intraarticular stem cell injections. for knee osteoarthritis and cartilage defects. And so, and those are culture expanded stem cells.

And so, the fact that, and the reason I bring Japan up too, because it's not like Columbia or Mexico or Panama, some random country that doesn't really have any sort of developed economy and like rigorous, like Japan has like rigorous standards. Like they're very meticulous with everything.

And so, the fact that, and the reason I bring Japan up too, because it's not like Columbia or Mexico or Panama, some random country that doesn't really have any sort of developed economy and like rigorous, like Japan has like rigorous standards. Like they're very meticulous with everything.

And so to me, the fact that they're able to approve, not only approve it, but actually have insurance companies reimburse people already just shows you like what's possible. But I think America, there's just so many politics, right? And the politics, unfortunately, affect the ability for us to offer these to patients.

And so to me, the fact that they're able to approve, not only approve it, but actually have insurance companies reimburse people already just shows you like what's possible. But I think America, there's just so many politics, right? And the politics, unfortunately, affect the ability for us to offer these to patients.